(Q40506025)

21 September 2017

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab (English)

1 reference

21 September 2017

0 references

1 reference

20

1 reference

21 September 2017

22

Dirk Schadendorf

1 reference

21 September 2017

Paolo Antonio Ascierto

24

object named as

Paolo A Ascierto

1 reference

21 September 2017

27

Jedd D Wolchok

1 reference

21 September 2017

7

Ester Simeone

1 reference

21 September 2017

21

Christian Blank

1 reference

21 September 2017

23

Reinhard Dummer

1 reference

21 September 2017

Benjamin Weide

1

1 reference

21 September 2017

Alexander Martens

2

1 reference

21 September 2017

Jessica C Hassel

3

1 reference

21 September 2017

Carola Berking

4

1 reference

21 September 2017

Michael A Postow

5

1 reference

21 September 2017

Kees Bisschop

6

1 reference

21 September 2017

Johanna Mangana

8

1 reference

21 September 2017

Bastian Schilling

9

1 reference

21 September 2017

Anna Maria Di Giacomo

10

1 reference

21 September 2017

Nicole Brenner

11

1 reference

21 September 2017

Katharina Kähler

12

1 reference

21 September 2017

Lucie Heinzerling

13

1 reference

21 September 2017

Ralf Gutzmer

14

1 reference

21 September 2017

Armin Bender

15

1 reference

21 September 2017

Christoffer Gebhardt

16

1 reference

21 September 2017

Emanuela Romano

17

1 reference

21 September 2017

Friedegund Meier

18

1 reference

21 September 2017

Peter Martus

19

1 reference

21 September 2017

Geke Hospers

25

1 reference

21 September 2017

Claus Garbe

26

1 reference

21 September 2017

language of work or name

English

0 references

publication date

16 May 2016

1 reference

21 September 2017

Clinical Cancer Research

1 reference

21 September 2017

22

1 reference

21 September 2017

22

1 reference

21 September 2017

5487-5496

1 reference

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.

21 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Pembrolizumab for the treatment of non-small-cell lung cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Pembrolizumab versus Ipilimumab in Advanced Melanoma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

PD-1 blockade induces responses by inhibiting adaptive immune resistance

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Genetic basis for clinical response to CTLA-4 blockade in melanoma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Nivolumab in previously untreated melanoma without BRAF mutation

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

The blockade of immune checkpoints in cancer immunotherapy

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Final version of 2009 AJCC melanoma staging and classification

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

PD-1 and its ligands in tolerance and immunity

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells.

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis

2 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5572569

X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization

2 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27185375

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27185375

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1078-0432.CCR-16-0127

1 reference

21 September 2017

1 reference

21 September 2017

PubMed publication ID

27185375

1 reference